<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Biosciences</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EBF62057-C51F-47BB-9B80-D3AA4A7ACD29"><gtr:id>EBF62057-C51F-47BB-9B80-D3AA4A7ACD29</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>B.</gtr:otherNames><gtr:surname>Dunnett</gtr:surname><gtr:orcidId>0000-0003-1826-1578</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/53E7EF11-FCED-4F39-89E8-38E69990FC29"><gtr:id>53E7EF11-FCED-4F39-89E8-38E69990FC29</gtr:id><gtr:firstName>Anne Elizabeth</gtr:firstName><gtr:surname>Rosser</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0200489"><gtr:id>054A5D53-27AD-4D97-AAE0-630A76C40C79</gtr:id><gtr:title>SWIFT - the South Wales Initiative for Neural Transplantation in HD</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0200489</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-12-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-03-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>241139</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>results included in multiple public and academic lectures and seminars</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>83E6D501-D27B-4BFA-9CBB-BF0969616833</gtr:id><gtr:impact>results included in multiple public and academic lectures and seminars

various</gtr:impact><gtr:outcomeId>2B80FAEA334</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AD398EBE-E85D-40C2-85AE-6D467D3358B5</gtr:id><gtr:impact>I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

various</gtr:impact><gtr:outcomeId>23C57C21F20</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>results included in multiple public and academic lectures and seminars</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>5B77698B-0BB1-4A8F-A6C5-7FC3A2C5066D</gtr:id><gtr:impact>results included in multiple public and academic lectures and seminars

various</gtr:impact><gtr:outcomeId>A1F186CD181</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>86804925-E363-4737-ADF5-27F661C3123C</gtr:id><gtr:impact>I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

various</gtr:impact><gtr:outcomeId>757CF680ED8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>E257A171-B031-4877-B25E-C5A3F1C0C365</gtr:id><gtr:impact>10-15 presentations to HDA and PDS patient groups. I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

various</gtr:impact><gtr:outcomeId>4E533867798</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>10-15 presentations to HDA and PDS patient groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>69E0CE97-07F4-4B16-BCE5-C6EFCDD3C4F4</gtr:id><gtr:impact>10-15 presentations to HDA and PDS patient groups. I present regular medical and lay seminars around the country and internationally. I am afraid I am unable to list all the individual presentations.

academic, medical and patient contacts</gtr:impact><gtr:outcomeId>014EB56EA63</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>873507</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>REPLACES Restorative plasticity at corticostriatal excitatory synapses (4.2m euros across 12 participants)</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E7996C33-908D-477E-B89F-321947E3E666</gtr:id><gtr:outcomeId>AFB44C285B60</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2941590</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>EC34C7E7-C5F8-4197-BBBD-510F7227C759</gtr:id><gtr:outcomeId>E9F39960E7C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>8F12E5FF-640B-4489-9161-9FCB82B02548</gtr:id><gtr:impact>Targetted direction, policy and funding of UK stem cell research .</gtr:impact><gtr:outcomeId>5AA8378353A</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>regular citations in clinical reviews and publications</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>37F736A1-6C05-4711-94A8-02356582054D</gtr:id><gtr:impact>influence on development of NECTAR and ASNTR guidelines</gtr:impact><gtr:outcomeId>35DB9587696</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC stem cell</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>34FFCE2F-7D26-4916-B88C-83E807D49727</gtr:id><gtr:impact>I participate in the MRC Stem Cell Bank User's group and participate regularly in MRC stem cell policy and funding strategy meetings at Head Office.</gtr:impact><gtr:outcomeId>F2D8A6F3BAF</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC Stem Cells</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>86BA3DBE-D130-4A94-96E5-FD9DEC79D9B8</gtr:id><gtr:impact>I participate in the MRC UK Stem Cell Bank users group and contribute regularly to the policy discussions at head office on stem cell strategy and funding.</gtr:impact><gtr:outcomeId>7E9135DE564</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>GTAC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>C8257470-3B0B-4189-A47D-7E186F9CE29E</gtr:id><gtr:impact>member of GTAC committee reviewing applications and developing policy on stem cell and gene therapy trials in the UK</gtr:impact><gtr:outcomeId>80395A16996</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citations in clinical guidelines and reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D700466D-9A01-4261-B98B-5721493ABA5A</gtr:id><gtr:impact>we contribute to ongoing debate and updating of guidelines on ethical sourcing of human fetal tissues for research and clinical cell transplantation.</gtr:impact><gtr:outcomeId>0A7A1912D35</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>GTAC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>76CFCAA2-A019-48D5-921C-EFC0808C3B09</gtr:id><gtr:impact>development of national ethical and regulatory guidelines</gtr:impact><gtr:outcomeId>2F7263565E5</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC stem cells</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>3F181F06-1BAB-4AB8-B7FE-0E989366563C</gtr:id><gtr:impact>I participate in the MRC Stem Cell Bank User's group and participate regularly in MRC stem cell policy and funding strategy meetings at Head Office.</gtr:impact><gtr:outcomeId>046F92CC2E5</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Validation of alternative protocols for consented collection of human fetal tissue</gtr:description><gtr:id>62FA9898-A5F9-468E-8F85-2DBDC32BE765</gtr:id><gtr:impact>Resolves the outstanding block on limited tissue availability to allow multiple international research and clinical trials to resume.</gtr:impact><gtr:outcomeId>CD8A8553171</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mTOPs</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5D83895D-5118-4E77-8016-D3C2B887BC23</gtr:id><gtr:title>Human stem cells for CNS repair.</gtr:title><gtr:parentPublicationTitle>Cell and tissue research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4deb31f760faf1ed0b3297504f95ebb"><gtr:id>e4deb31f760faf1ed0b3297504f95ebb</gtr:id><gtr:otherNames>Zietlow R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-766X</gtr:issn><gtr:outcomeId>3CAFF857D08</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89449044-8365-4633-BAEE-12A957713DBE</gtr:id><gtr:title>Medium spiny neurons for transplantation in Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9dd96bb733c0726221ef84de4144119"><gtr:id>f9dd96bb733c0726221ef84de4144119</gtr:id><gtr:otherNames>Kelly CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>34BE1103642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC515C47-46EE-43FE-9A1F-DE2E0A828A85</gtr:id><gtr:title>Cell transplantation for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fd04f4373f41cb55380f3706063e39a"><gtr:id>2fd04f4373f41cb55380f3706063e39a</gtr:id><gtr:otherNames>Rosser AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>4729294C50B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CC2725D-D887-4E7F-8A64-C98BF7E21EFA</gtr:id><gtr:title>Neonatal desensitization allows long-term survival of neural xenotransplants without immunosuppression.</gtr:title><gtr:parentPublicationTitle>Nature methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9dd96bb733c0726221ef84de4144119"><gtr:id>f9dd96bb733c0726221ef84de4144119</gtr:id><gtr:otherNames>Kelly CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1548-7091</gtr:issn><gtr:outcomeId>CFE144AB904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B557BD06-F1FD-4AB9-8269-D825371FD382</gtr:id><gtr:title>Membrane permeability coefficients of murine primary neural brain cells in the presence of cryoprotectant.</gtr:title><gtr:parentPublicationTitle>Cryobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8310c0298b94e524a3fecbc76cf8a13"><gtr:id>d8310c0298b94e524a3fecbc76cf8a13</gtr:id><gtr:otherNames>Paynter SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0011-2240</gtr:issn><gtr:outcomeId>39001DB9855</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06193203-3831-4BE4-BEB0-536BFEDD4778</gtr:id><gtr:title>Stem cell transplantation for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2edda089a98ce18159ce9576c85efbc2"><gtr:id>2edda089a98ce18159ce9576c85efbc2</gtr:id><gtr:otherNames>Dunnett SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>99769789DCD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB2C9C15-F1D5-44B9-BF46-B5C2B2CAECD7</gtr:id><gtr:title>Neural transplantation in Huntington's disease: the NEST-UK donor tissue microbiological screening program and review of the literature.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/176e5b4a01a03f15d6b91f8451d3ea30"><gtr:id>176e5b4a01a03f15d6b91f8451d3ea30</gtr:id><gtr:otherNames>Farrington M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn><gtr:outcomeId>47DFEC34A84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73FF14F4-A3A1-4140-8912-A46FD390FA66</gtr:id><gtr:title>Stem cell transplantation for neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fd04f4373f41cb55380f3706063e39a"><gtr:id>2fd04f4373f41cb55380f3706063e39a</gtr:id><gtr:otherNames>Rosser AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>565321C5401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8AAA15E-2CE6-4495-A3AC-AFB7DF91CFA8</gtr:id><gtr:title>Cell transplantation for Huntington's disease Should we continue?</gtr:title><gtr:parentPublicationTitle>Brain research bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2edda089a98ce18159ce9576c85efbc2"><gtr:id>2edda089a98ce18159ce9576c85efbc2</gtr:id><gtr:otherNames>Dunnett SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0361-9230</gtr:issn><gtr:outcomeId>96A1E8784DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1A1D5B3-B308-4A33-A155-5FDCDF0D9E3D</gtr:id><gtr:title>Pharmaceutical, cellular and genetic therapies for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a68df34dbc1cd36a0da840dd2d9876db"><gtr:id>a68df34dbc1cd36a0da840dd2d9876db</gtr:id><gtr:otherNames>Handley OJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>F43CFC19E25</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0200489</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>